Cassava Sciences Inc (USD)
SAVA
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range2.85 | 3.02
52-Wk Range- | -
Last Close2.99
Mkt Cap (m)74.09
Dividend yield-
ISINUS14817C1071
Volume905,859.00
Exchange VenueNAS

Company Profile

Pain Therapeutics Inc is a biopharmaceutical company that develops novel drugs. The Company has four drug candidates in clinical programs, including Remoxy, Oxytrex, PTI-202 and a novel radio-labeled monoclonal antibody to treat metastatic melanoma.

Key Information
Price/Earning-
Price/Book2.98
Price/Sales-
P/CF-
Rev Growth (3 year avg)0.00
EPS Growth (3 year avg)-
Operating Margin % -
Net Margin %-
Return on Equity-22.20
Debt/Equity0.00

Documents

Prospectus
en 05/05/2020
Annual Report
en 31/12/2019

Please refer to the below issuer website for further documents.

http://www.cassavasciences.com

Financials

Income Statement
USD201420152016201720182019
Revenue (m)0.000.000.000.000.000.00
Operating Income (m)-12.43-14.20-14.96-11.95-6.66-4.96
Net Income (m)-12.39-14.15-14.85-11.91-6.56-4.63
Basic EPS-1.89-2.17-2.31-1.82-0.61-0.27
Avg. Diluted Shares Outstanding (m)6.476.546.526.5410.6817.41
Balance Sheet
USD201420152016201720182019
Current Assets (m)40.8331.6919.0710.6620.0423.35
Non Current Assets (m)0.110.210.300.210.110.14
Total Assets (m)40.9131.9219.3010.8320.1423.49
Current Liabilities (m)0.852.550.671.130.511.39
Total Liabilities (m)------
Total Equity (m)40.0629.3718.649.7019.6322.10
Cash Flows
USD201420152016201720182019
Operating Cash Flows (m)-9.55-9.05-12.23-8.24-4.77-2.51
Capital Expenditure (m)-0.08-0.20-0.08---0.02
Figures are quoted in USD unless stated otherwise
-0.13 (-4.35%)
$
2.86
Last Price